Skip to main content
Hanna Sanoff, MD, Oncology, Chapel Hill, NC

Hanna K Sanoff MD

Gastrointestinal Cancer


Associate Professor of Medicine, University of North Carolina at Chapel Hill

Join to View Full Profile
  • 170 Manning Dr Cb 7305Chapel Hill, NC 27599

Dr. Sanoff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of North Carolina Hospitals
    University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2003 - 2006
  • University of North Carolina Hospitals
    University of North Carolina HospitalsResidency, Internal Medicine, 2000 - 2003
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2000
  • University of North Carolina
    University of North CarolinaMPH

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2000 - 2025
  • VA State Medical License
    VA State Medical License 2009 - 2012
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effectiveness of a Multimedia Educational Intervention to Improve Understanding of the Risks and Benefits of Palliative Chemotherapy in Patients with Advanced Cancer  
    Andrea C Enzinger, Hanna Sanoff, Deborah Schrag, JAMA Oncology

Other

Authored Content

  • Managing Grief, Loss, and Connection in Oncology—What COVID-19 Has TakenJuly 2020
  • Managing Grief, Loss, and Connection in Oncology—What COVID-19 Has TakenJuly 2020
  • Telemedicine for Cancer Care in the Time of COVID-19July 2020

Press Mentions

  • FDA’s ODAC: Risks Outweigh Benefits for Checkpoint Inhibitors in Some Cancers
    FDA’s ODAC: Risks Outweigh Benefits for Checkpoint Inhibitors in Some CancersSeptember 30th, 2024
  • Carolina Cancer Experts Available for Interviews
    Carolina Cancer Experts Available for InterviewsMay 19th, 2023
  • Scientists Intrigued by Treatment That Put Every Single Patient's Cancer into Remission
    Scientists Intrigued by Treatment That Put Every Single Patient's Cancer into RemissionAugust 11th, 2022
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: